Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
It would certainly be good to see more upside from here. We all know there's plenty room for it.
Sure thing Dan, if we land some good contracts it would be at a good solid premium too.
Well, you got to be in it to win it. We only need a small % of that market to do over and above any of our expectations.
Hey, look. It's blue! Be nice to get a run up to results next week.
Email defo done the trick lol
Dan,
great job with the email. LR knows the script. Don't F with the real shareholders who hold real stock :)
Anyway...there we have it...what's all the fuss about? Results will be more or less same time as last year.
Anyone been watching it? It's a bit better than Sky news.
Needs a bit of work in terms of visuals and audio issues but the content is a bit better :)
lol Nothing wrong with a sarcastic email to give em a jolt
Bakky,
we all appear to have come to the same conclusion within a few days of each other to use the filter. It says it all really.
We should be able to communicate a lot easier now and with less distractions as the green boxes are our salvation.
Positivity is the way ahead.
Positive vibes bring positive outcomes and positive people.
Spin,
exactly how I feel mate. Swathes of good news have been delivered over the last 12 months which is the touch paper and we just now need one or two with the gun powder and we will be off.
All that good news will be put in one big pot and we will get our rewards.
Positive vibes yield positive outcomes.
Spin,
those fundi's might be looking really good now. We just need the low down from the boss.
It will come mate. We will be thriving when it does.
Positivity is the key. Keeping positive is what makes holding through the hard time that bit easier.
Andy,
In case you missed my post from last week, I've filtered twix and colin and have not interacted with them for over a week.
That will continue. I see a lot of filtered responses in todays chat which I can only assume are from the two I have filtered.
I have not been posting in reaction to anything they may or may not have said.
Anything I have posted today has been in response to others and has not been to instigate anything but to simply make a couple of valid points.
Hemo,
we are where we are because of last years results. So I never missed the point. I addressed it.
Bottom line is your expectations are more demanding than mine are. That's fine. I respect your POV.
I don't care when they present with the results because they will present them when they are ready. I just have a more relaxed view when investing on AIM.
Like I've said a 100 times. It's not for everyone. Some people should just avoid AIM co's or at least learn to take the rough with the smooth.
I think the level of opportunity for YGEN is now huge, our products & offerings are vast and the potential is now greater than at anytime in the past. It takes time to position yourself in that way and the results can take longer. I'm not sweating it though.
Our tentacles are expanding too: This is overlooked to a degree but not to be sniffed at:
Alliance Global is the largest biomedical gateway in the Middle East, Africa, and Asia and is both a well-respected and a long-term partner for many international and U.S. diagnostics groups looking to pursue a strategy of expansion in these regions. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic users in the regions' emerging healthcare market. AGBL is a well-positioned platform agnostic partner for Yourgene, working with key providers of both PCR and sequencing technologies. AGBL will be focusing on Yourgene's product portfolio of non-invasive prenatal testing ('NIPT'), the reproductive health range including Cystic Fibrosis and QST*R rapid aneuploidy analysis, DPYD genotyping and the new size selection and enrichment technologies, Yourgene QS250 and LightBench™.
Lyn Rees, CEO of Yourgene, said: "This partnership with AGBL is a really exciting progression for Yourgene and our product portfolio as we continue to expand into further territories. AGBL will provide a strong and well positioned channel to allow us to deliver and drive growth for our current and future products. This is a key international market for Yourgene and we look forward to working with AGBL and utilising their expertise to secure further market penetration and geographic expansion."
You could well be right bakky but they are spreading their tentacles in the space.
Shame they could have put a $1 billion offer in for Ygen :)
Anyway, Positivity wins the day. I'm sure things are ticking a long nicely and we will get some good news when they are ready to drop it. Still expecting a lot more from the US too.
I doubt Covid will be going anywhere anytime soon if these two are still investing.
Billionaires George Soros and Bill Gates are part of a consortium set to buy Mologic, a U.K.-based maker of Covid tests, in an effort to increase access to “affordable state-of-the-art medical technology around the world.
https://www.forbes.com/sites/daviddawkins/2021/07/19/george-soros-and-bill-gates-backed-consortium-to-buy-uk-maker-of-covid-lateral-flow-tests-for-41-million/?sh=5fc6d38b2687
Cheers Mala,
Abstract:
Developing an in vitro diagnostic device is often a complex and demanding process. Doing so in the midst of a pandemic and the IVD global supply chain stretched like never before, with project teams formed entirely via remote working and under intense time pressure takes this to another level. Clarigene: A pandemic diagnostic development story takes us through how Yourgene Health entered into the infectious disease space, including the major challenges and how they were overcome. Carefully working through market and customer needs enabled key design decisions to made, ultimately leading to a robust product being released onto the market. The implementation of the Clarigene SARS-CoV-2 test in the company’s service lab, including in house automation and development of wrap around sample tracking software, demonstrated the product to be a robust and scalable test that could be applied quickly and effectively into any laboratory setting. In the face of multiple mutations in the viral genome, enhanced post-market surveillance and risk mitigation planning is key to ensuring any SARS-CoV-2 test can be relied upon to perform as expected as new strains arise.
You feel free to say what you like Hemo. I have no issue with POV.
My POV is we will be doing very well on several front but we need to get over this hump we hit during the lockdown. It hampered us but we will have learned a lot from it and will no doubt be doing very well now but too late to save last years bottom line. It is what it is.
1 share trades are old tricks by the chancers on AIM from back in the day but I've seen them coincide with an RNS in the past so we will see.
We are due some positive news!!
Those kind of figures would do us fine for starters bakky. I expect more going forward though once the flood gates open through the airports etc